Try our beta test site

Novel Diagnostics for Ocular Structure

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborator:
National Eye Institute (NEI)
Information provided by (Responsible Party):
New York University School of Medicine
ClinicalTrials.gov Identifier:
NCT00286637
First received: February 2, 2006
Last updated: January 11, 2017
Last verified: January 2017
  Purpose
The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases

Condition
Glaucoma
Macular Disease

Study Type: Observational
Official Title: Optical Coherence Tomography Domain Reflectometry & Optical Coherence Tomography Measurements of Intraocular Structure

Resource links provided by NLM:


Further study details as provided by New York University School of Medicine:

Primary Outcome Measures:
  • Novel Diagnostics for Ocular Structure [ Time Frame: 5 years ]
    The purpose of this research is to evaluate novel technologies for the assessment of ocular structure and function, including the scanning device called Optical Coherence Tomography (OCT). We will test the OCT and other devices in their ability to image diseases of the eye and also compare the measurements made with OCT to those of other imaging and visual field devices approved by the Food and Drug Administration (FDA). OCT may be useful for the early diagnosis and monitoring of a variety of types of eye diseases


Enrollment: 2767
Study Start Date: January 1995
Estimated Study Completion Date: January 2020
Estimated Primary Completion Date: January 2018 (Final data collection date for primary outcome measure)
  Show Detailed Description

  Eligibility

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Recruiting subjects male or female, ages beginning at 18 with Macular dgegeneration, diabetic retinopathy, and/or glaucoma. Can also be a normal/healthy subject.
Criteria

Inclusion Criteria:

  1. Age older than or equal to 18 years old
  2. Macular Degeneration, Diabetic Retinopathy, and/or glaucoma patients.
  3. Normal control subjects

Exclusion Criteria:

  1. Media opacity (lens, vitreous, cornea)
  2. Strabismus, nystagmus, or a condition that would prevent fixation.
  3. Inability to understand informed consent
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00286637

Locations
United States, Pennsylvania
University of Pittsburgh UPMC Eye Center
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
New York University School of Medicine
National Eye Institute (NEI)
Investigators
Study Chair: Joel S Schuman, MD University of Pittsburgh
  More Information

Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: New York University School of Medicine
ClinicalTrials.gov Identifier: NCT00286637     History of Changes
Other Study ID Numbers: R01EY013178-06  R01EY011289-21  P30EY008098 
Study First Received: February 2, 2006
Last Updated: January 11, 2017
Individual Participant Data  
Plan to Share IPD: Undecided

Keywords provided by New York University School of Medicine:
OCT
CSLO
SLP
Perimetry
electrophysiology
glaucoma
macular degeneration
retinopathy
diabetes
macular hole

Additional relevant MeSH terms:
Glaucoma
Ocular Hypertension
Eye Diseases

ClinicalTrials.gov processed this record on February 23, 2017